Col·legi de Farmacèutics de Barcelona
/ Circ. Farm. 2014 vol. 72 núm. 1
13
FARMACOT
BIBLIOGRAFIA
1.
Casajuana J, Aragonès R. Hiperplasia benigna de próstata. Guías Clínicas
Fisterra.
a:
-benigna-prostata/#1026
2.
Bobé F, Milozzi J, Pérez D i el Grupo de Urología de la Sociedad Catalana
de Medicina Familiar y Comunitaria (CAMFiC). La hiperplasia benigna de
próstata en las consultas de atención primaria. JANO 2007;1654:23-29
3.
Criterios de derivación en hiperplasia benigna de próstata para atención
primaria. J Castiñeiras Fernández, J.M. Cozar Olmo, A. Fernández-Pro,
J.A. Martín, F.J. Brenes Bermúdez, E. Naval Pulido, J.M. Molero, D. Pérez
Morales. Actas Urol Esp. 2010;34(1):24-34
4.
Wilt TJ, N’Dow J. Benign prostatic hyperplasia. Part 1- diagnosis. BMJ.
2008 Jan 19;336(7636):146-9
5.
Spatafora S, Conti G, Perachino M, Casarico A, Mazzi G, Papagayo LP.
Evidence-based guidelines for the management of lower urinary tract
symptoms related to uncomplicated benign prostatic hyperplasia in Italy:
updated summary. Curr Med Res Opin. 2007; 23 (7):1715-32.
6.
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, De la
Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up
of men with lower urinary tract symptoms suggestive of benign prostatic
obstruction (BPH guidelines). Eur Urol. 2004; 46:547-54.
7.
Cózar JM, Castiñeiras J. Criterios de derivación de la hiperplasia benigna
de próstata para atención pimaria. Versión 2011. Actas Urol Esp. 2012
Mar;36(3):203-4
8.
Badia X, Garcia M, Dal Re R. Ten language translation and harmonization
of International Prostate Symptom Score: developing a methodology for
multinational clinical trials. Eur Urol. 1997; 31:129-40.
9.
The management of lower urinary tract symptoms in men. NICE clinical
guideline 97 (2010). Disponible a:
10.
US. Preventive Services Task Force. Screening for prostate cancer: US.
Preventive Services Task Force recommendation statement. Ann Intern
med. 2008; 3 (149):185-91.
11.
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA,
et al. Serumprostate-specific antigen in a community-based population of
healthy men. Establishment of age-specific reference ranges. JAMA.
1993;270:860-4
12.
Cozar JM, Solsona E, Brenes F, Fernández-Pro A, León F, Molero JM, Pérez
JF, Rodríguez MP, Huerta A, Pérez-Escolano I. Manejo asistencial del pa-
ciente con hiperplasia benigna de próstata en España. Actas Urol Esp.
2011 Nov-Dec;35(10):580-8.
13.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel
MC, N’Dow J, Nordling J, de la Rosette JJ. Guidelines on Management
of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obs-
truction (BPO). European Association of Urology. 2012. Disponible a:
14.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM,
Kusek JW, et al. The long-term effect of doxazosin, finasteride, and com-
bination therapy on the clinical progression of benign prostatic hyperpla-
sia. N Engl J Med. 2003;349:2387-8.
15.
Wilt T J, N’Dow J. Benign prostatic hyperplasia. Part 2- Management.
BMJ. 2008;336:206-210.
16.
Barry MJ, WillifordWO, Chang Y, Machi M, Jones KM, Walker-Corkery E
et al. Benign prostatic hyperplasia specific health status measures in cli-
nical research: Howmuch change in the American Urological Association
symptom index and the benign prostatic hyperplasia impact index is per-
ceptible to patients? J Urol. 1995;154:1770-4.
17.
Manejo de la Hiperplasia Benigna de próstata (HBP).INFAC. 2012; 20(3).
Disponible a:
18.
Strittmatter F, Gratzke C, Stief CG, Hedlund P. Current pharmacological
treatment options for male lower urinary tract symptoms. Expert Opin
Pharmacother. 2013 Jun;14(8):1043-54
19.
Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn
CG, Serni S, Mirone V, Carini M, Maggi M. A systematic reviewandmeta-
analysis on the use of phosphodiesterase 5 inhibitors alone or in combina-
tion with α-blockers for lower urinary tract symptoms due to benign pros-
tatic hyperplasia. Eur Urol. 2012 May;61(5):994-1003
20.
Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA,
Marberger M, Montorsi F, Novara G, OelkeM, Porst H, Roehrborn C, Stief
C, McVary KT. Systematic review of combination drug therapy for non-
neurogenic male lower urinary tract symptoms. Eur Urol. 2013
Aug;64(2):228-43.
21.
Debruyne FM. Alphablockers: Are all created equal? Urology. 2000;56:20-2.
22.
Fitxa tècnica d’alfuzosina. Disponible a:
23.
Fitxa tècnica de doxazosina. Disponible a
24.
Fitxa tècnica de prazosina. Disponible a
25.
Fitxa tècnica de terazosina. Disponible a
26.
Fitxa tècnica de silodosina. Disponible a:
27.
Fitxa tècnica de tamsulosina. Disponible a
28.
Fitxa tècnica de finasterida. Disponible a:
29.
Fitxa tècnica de dutasterida. Disponible a:
30.
Marberger M, Freedland SJ, Andriole GL, EmbertonM, Pettaway C, Mon-
torsi F, Teloken C, Rittmaster RS, Somerville MC, Castro
of
prostate-specific antigen (PSA) rise as a marker of prostate cancer in men
treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012
Apr; 109(8):1162-9
31.
Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase
inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur
Urol. 2003;44:82-8.
32.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and sa-
fety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in
men with benign prostatic hyperplasia. Urology. 2002;60:434-41.
33.
FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs)
may increase the risk of a more serious form of prostate cancer. 2011.
Drug Safety Update Disponible a:
34.
Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use
of 5α-reductase inhibitors for lower urinary tract symptoms and risk of
prostate cancer in Swedish men: nationwide, population based case-
control
. 2013 Jun 18;346:f3406
35.
Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, et
al. The effects of dutasteride, tamsulosin and combination therapy on
lower urinary tract symptoms in men with benign prostatic hyperplasia
and prostatic enlargement: 2-year results from the CombAT study. J Urol.
2008;179:616-21.
36.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I,
Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of
combination therapy with dutasteride and tamsulosin on clinical outco-
mes inmenwith symptomatic benign prostatic hyperplasia: 4-year results
from the CombAT study. Eur Urol. 2010 Jan;57(1):123-31.
37.
Comité de Evaluación de Nuevos Medicamentos de Navarra. Nuevo me-
dicamentoaexamen:Dutasterida/Tamsulosina.2011.Disponiblea
38.
Fitoterapia en el tratamiento de la hiperplasia benigna de próstata.. Bol
Ter Andal. 2009; 25 (4). Disponible a
39.
Morán E, Budía A, Broseta E, Boronat F. Fitoterapia en Urología. Evidencia
científica actual de su aplicación en hiperplasia benigna de próstata y
adenocarcinoma de próstata. Actas Urol Esp. 2013 Feb;37(2):114-9.
40.
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for
benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012 Dec
12;12:CD001423
